BiotechTube

pramlintide acetate + sibutramine + phentermine + placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Overweight

Conditions

Overweight, Obesity

Trial Timeline

Nov 1, 2006 → Aug 1, 2007

NCT ID
NCT00402077

About pramlintide acetate + sibutramine + phentermine + placebo

pramlintide acetate + sibutramine + phentermine + placebo is a phase 2 stage product being developed by AstraZeneca for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT00402077. Target conditions include Overweight, Obesity.

What happened to similar drugs?

1 of 20 similar drugs in Overweight were approved

Approved (1) Terminated (0) Active (19)
✅AripiprazoleBristol Myers SquibbApproved
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Eloralintide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Tirzepatide + PlaceboEli LillyPhase 3
🔄Maridebart cafraglutide + PlaceboAmgenPhase 3
🔄Semaglutide + Semaglutide PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00402077Phase 2Completed

Competing Products

20 competing products in Overweight

See all competitors
ProductCompanyStageHype Score
TERN-601Terns PharmaceuticalsPhase 2
32
LY3457263 + Tirzepatide + PlaceboEli LillyPhase 1
29
LY3305677 + PlaceboEli LillyPhase 1
29
LY3537031 + PlaceboEli LillyPhase 1
33
Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection)Eli LillyPhase 2
42
Eloralintide + PlaceboEli LillyPhase 3
47
LY4064912 + LY4064912 + Placebo + PlaceboEli LillyPhase 1
36
LY3437943 + Ethinyl Estradiol + DrospirenoneEli LillyPhase 1
29
Tirzepatide + AcetaminophenEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 2
39
Eloralintide + PlaceboEli LillyPhase 3
47
LY3437943 + PlaceboEli LillyPhase 1
29
LY3502970 + PlaceboEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
44
Eloralintide and Tirzepatide + EloralintideEli LillyPhase 1
29
Tirzepatide + PlaceboEli LillyPhase 3
40
LY3541105 + PlaceboEli LillyPhase 1
29
Retatrutide + PlaceboEli LillyPhase 2
35
LY4167586 + Placebo + LY4167586Eli LillyPhase 1
36
AZD9550 + AZD6234 + Placebo comparatorAstraZenecaPhase 2
39